Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijd.13973 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer.
J Transl Med
December 2022
Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Background: Breast cancer is a complex disease with a highly immunosuppressive tumor microenvironment, and has limited clinical response to immune checkpoint blockade (ICB) therapy. T-helper 2 (Th2) cells, an important component of the tumor microenvironment (TME), play an essential role in regulation of tumor immunity. However, the deep relationship between Th2-mediated immunity and immune evasion in breast cancer remains enigmatic.
View Article and Find Full Text PDFSuccessful use of montelukast in eosinophilic gastroenteritis: a case report and a literature review.
BMC Gastroenterol
July 2021
Promedica Digestive Health Care, 5700 Monroe St, Suite 103, Sylvania, OH, USA.
Background: Eosinophilic gastrointestinal disorders, also known as eosinophilic gastroenteritis, are rare inflammatory conditions characterized by eosinophilic infiltration of different parts of the gastrointestinal tract, along with peripheral eosinophilia in most cases. Other known causes for gut eosinophilic infiltration must be excluded to confirm the diagnosis of eosinophilic gastroenteritis. Symptoms of the disorder depend on the affected gastrointestinal tract segment and depth of involvement.
View Article and Find Full Text PDFSuplatast tosilate in patients with interstitial cystitis: Efficacy and treatment possibilities, with suggestions for future assessments.
Int J Urol
June 2019
Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Objective: Suplatast tosilate, a Th2 cytokine inhibitor, was predicted to relieve interstitial cystitis symptoms. Four studies with suplatast tosilate in Japanese interstitial cystitis patients have been conducted: a single-arm clinical study, a phase II dose-ranging trial, a phase III trial with placebo, and a second phase PIII trial with placebo. Treatment efficacy was observed in the first two studies; however, in the phase PIII trials, no significant difference in interstitial cystitis symptom score changes was observed between suplatast tosilate and placebo.
View Article and Find Full Text PDFEfficacy of suplatast tosilate in a case of recurrent eosinophilic annular erythema.
Int J Dermatol
September 2018
Department of Dermatology, Tenri Hospital, Nara, Japan.
Immunotherapy options for painful bladder syndrome: what's the potential?
Expert Opin Biol Ther
December 2017
c Hadassah and Hebrew University Hospital, Urology Department , Jerusalem , Israel.
Painful bladder syndrome/interstitial cystitis (PBS/IC) is an enigmatic disease characterized by lack of evidence-based knowledge and an ongoing scientific debate regarding its definition, pathogenesis, diagnostic and treatment algorithm. An autoimmune theory for PBS/IC etiology has suggested immunotherapy as a potential treatment choice. Areas covered: In this review, the authors report existing and future immunotherapeutic options, potentially valuable to the management of PBS/IC while evidence for the immunological aspect of PBS/IC pathogenesis are also presented.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!